Drug Safety Considerations During Controlled Ovarian Stimulation

Abstract

Controlled ovarian stimulation (COS) is integral to assisted reproductive technologies (ART), maximizing oocyte yield while balancing safety. However, the pharmacological agents used carry risk for complications including ovarian hyperstimulation syndrome (OHSS), thromboembolic events, and long-term sequelae. This review synthesizes current evidence on drug safety during COS, focusing on epidemiology, pathophysiology, risk stratification, clinical features, diagnostic pathways, management, and emerging safety strategies. Recent guidelines and advances in pharmacologic protocols are discussed to inform optimal, individualized care for patients undergoing COS.

Introduction

Controlled ovarian stimulation (COS) forms the cornerstone of in vitro fertilization (IVF) and other ART procedures, aiming to induce multifollicular development through exogenous gonadotropin administration. The selection, dosing, and monitoring of pharmacologic agents are critical, as COS is associated with potential risks such as OHSS, venous thromboembolism (VTE), and rare but notable long-term health concerns. Drug safety during COS is therefore an essential consideration for reproductive endocrinologists, gynecologists, and fertility specialists. This review provides an evidence-based overview of the safety landscape of COS, considering recent research and evolving clinical guidelines.

Epidemiology / Disease Burden

COS is widely employed globally, with over 2 million ART cycles performed annually. The incidence of significant complications such as moderate-to-severe OHSS ranges from 1% to 5% in stimulated cycles, while mild forms can affect up to 30% of patients. Thromboembolic events, although relatively rare (incidence 0.1–2%), carry substantial morbidity. The burden of adverse drug effects is higher in certain populations, including patients with polycystic ovary syndrome (PCOS) and those with high ovarian reserve. Understanding these epidemiological patterns is key to individualized risk mitigation.

Pathophysiology

The primary agents in COS recombinant or urinary FSH, human menopausal gonadotropin (hMG), and GnRH analogues modulate the hypothalamic-pituitary-ovarian axis to induce follicular growth. OHSS, the most serious complication, arises from excessive ovarian response, leading to increased vascular permeability mediated by vasoactive substances such as vascular endothelial growth factor (VEGF). Thromboembolic risk is heightened by hemoconcentration secondary to third spacing of fluids and by estrogen-induced hypercoagulability. Possible long-term effects, such as risk for hormone-dependent malignancies, remain under investigation, emphasizing the need for ongoing vigilance.

Risk Factors

Patient-specific factors influencing drug safety in COS include young age, low body mass index, PCOS, high antral follicle count, elevated anti-Müllerian hormone (AMH), and prior high ovarian responsiveness. Protocol-related factors, such as high total gonadotropin dose, use of hCG for triggering, and long-acting gonadotropin regimens, also elevate risk. Identifying these factors allows for risk stratification and tailored stimulation protocols, reducing the likelihood of severe adverse events.

Clinical Features

OHSS manifests with abdominal discomfort, distension, nausea, vomiting, and in severe cases, ascites, pleural effusion, oliguria, and hemodynamic instability. Thromboembolic events may present as deep vein thrombosis or pulmonary embolism, often in the context of severe OHSS. Drug-specific side effects include injection site reactions, allergic responses, and rarely, ovarian torsion or infection. Recognizing early clinical features and distinguishing mild from severe forms is crucial for prompt intervention.

Diagnosis

The diagnosis of OHSS is clinical, supported by ultrasound findings (enlarged ovaries, ascites) and laboratory markers (hemoconcentration, electrolyte derangements). Severity is graded based on symptomatology and objective findings. Suspicion for thromboembolic complications warrants imaging such as Doppler ultrasound or CT pulmonary angiography. Monitoring protocols during COS involve serial ultrasounds and estradiol measurements to anticipate and preempt excessive ovarian response, thereby enhancing safety.

Treatment & Management

Prevention is the primary strategy for drug safety in COS. Individualized dosing based on ovarian reserve markers, use of GnRH antagonist protocols, and judicious application of hCG for ovulation triggering are standard risk-reduction measures. In high-risk patients, coasting (withholding gonadotropins), GnRH agonist trigger, and freeze-all embryo strategies are effective. Management of OHSS is supportive, involving fluid management, thromboembolism prophylaxis, and, in severe cases, hospitalization for monitoring and intervention. Prompt cessation of stimulation and cycle cancellation may be warranted in extreme cases.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advancements in COS safety. The introduction of long-acting FSH preparations and biosimilars offers alternative stimulation regimens with comparable efficacy and safety profiles. Kisspeptin analogues and dual-trigger protocols are being explored for safer ovulation induction. The adoption of individualized, algorithm-driven stimulation protocols incorporating AMH and antral follicle count has reduced the incidence of severe OHSS. Ongoing research into biomarkers and genetic predictors holds promise for further personalization of COS and minimization of drug-related risks.

Guideline Recommendations

Leading societies such as the American Society for Reproductive Medicine (ASRM) and European Society of Human Reproduction and Embryology (ESHRE) emphasize individualized COS protocols to mitigate adverse events. Key recommendations include baseline ovarian reserve assessment, use of GnRH antagonist protocols in high-risk women, consideration of GnRH agonist trigger, and routine thromboprophylaxis in severe OHSS. Guidelines advocate for patient counseling regarding risks, shared decision-making, and rigorous monitoring throughout stimulation.

Conclusion

Drug safety during controlled ovarian stimulation is paramount to optimizing reproductive outcomes and minimizing harm. Advances in risk assessment, individualized stimulation strategies, and emerging pharmacologic options have substantially improved the safety profile of COS. Adherence to evidence-based guidelines and vigilance for adverse effects are essential for clinicians managing patients in ART cycles. Future research should focus on refining predictive tools and novel agents to further enhance safety while maintaining therapeutic efficacy.